Extra-virgin olive oil during cardiac rehabilitation in heart failure with reduced ejection fraction
Tests daily extra-virgin olive oil alongside cardiac rehabilitation in adults with weakened heart pumping.
Key facts
- Who runs it
- Old Dominion University
- Where
- Norfolk, United StatesSee the site
- Trial code
- Registry title
- Olive Oil Supplementation for Heart Failure With Reduced Ejection Fraction
- Status
- Recruiting
- People taking part
- 40 people, planned
- Started
- 1 Jul 2026
- Expected to end
- 31 Mar 2028
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Extra-virgin olive oil
- Record updated
- 16 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with heart failure with reduced ejection fraction who are about to start a cardiac rehabilitation program. They would take extra-virgin olive oil daily for 12 weeks.
- Age
- 18 Years to 85 Years
- Sex
- All sexes can join.
- Disease stage
- Heart failure with reduced ejection fraction, with left ventricular ejection fraction ≤35 %.
- Earlier treatment
- Must be enrolled in the standard cardiac rehabilitation program at Sentara Cardiac Rehabilitation Center but not yet started it (has not attended the first session).
- Biomarker or test result
- Left ventricular ejection fraction ≤35 %.
Main reasons for not taking part
- Other illness expected to limit survival (for example, terminal illness)
- End-stage renal disease
- Unstable fluid overload
- Current pregnancy
- Habitual use of extra-virgin olive oil greater than 4 tablespoons per day
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Diagnosed with HFrEF with left ventricular ejection fraction ≤35 %
- Referred to and enrolled in the standard cardiac rehabilitation program at Sentara Cardiac Rehabilitation Center, but has not yet initiated/started cardiac rehabilitation (i.e., has not attended the first cardiac rehab session)
- Able and willing to comply with study procedures and provide informed consent
Who cannot take part
- Co-morbidity expected to limit survival (e.g., terminal illness)
- End-stage renal disease
- Known allergy or sensitivity to olive oil or its components
- Unstable fluid overload
- Current pregnancy (self-disclose)
- Habitual use of EVOO greater than 4 tablespoons per day
- Unwillingness or inability to incorporate EVOO or dietary recommendations
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Where in United States
- Strelitz Diabetes Center (Williams Hall)Norfolk, United StatesContact: Salvatore Carbone, PhD, RDNTaking people
About the trial
What the trial wants to find out
The OLEA-HF study aims to explore whether daily supplementation of extra-virgin olive oil (EVOO) for 12 weeks during participation in a cardiac rehabilitation program (standard of care) is feasible in patients with heart failure with reduced ejection fraction (HFrEF). The investigators will also determine the effects of EVOO on functional capacity and quality of life.
The 2 groups in the trial
- Extra-virgin olive oilTreatment being tested
- Standard of careNo study treatment, for comparison
Cardiac rehabilitation as part of standard of care
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Olive Oil Supplementation to Enhance Exercise Tolerance in Cardiac Rehabilitation in Patients With Heart Failure With Reduced Ejection Fraction: The OLEA-HF Study
- Plain-language title
- Extra-virgin olive oil during cardiac rehabilitation in heart failure with reduced ejection fractionGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07644806, who can take part
- Record updated
- 16 October 2026